Santen CEO's Clear Vision For World 'Built On Ability To See'
Ex-Japan Markets To Drive Growth
Executive Summary
CEO of Japanese ophthalmology specialist lays out clear-sighted business vision as track laid for expansion into global markets and new indications amid expiry challenges at home. New modalities are also being explored to meet needs in demanding disorders, Shigeo Taniuchi tells Scrip in an exclusive interview.
You may also be interested in...
Keeping Track: US FDA Clears Santen’s Omlonti, Fennec’s Pedmark; Lilly’s Retevmo Adds Tumor-Agnostic Claim
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker
Potential Santen, Centaur India Eye Care Alliance Off
Indian firm Centaur confirms to Scrip that a planned alliance with Santen for the Indian market is not going ahead, as the mid-sized Japanese ophthalmic specialist says it is looking to build up its direct presence in Asia.
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.